Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies-Reference-Cited by-同舟云学术

Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies

Published:2019-06 Issue:6 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Dong Lei¹,Zhai Xiao-Ying²,Yang Yi-Lei³,Wang Li²,Zhou Yue⁴,Shi Hai-Yan³,Tang Bo-Hao⁴,Wu Yue-E⁴,Yang Fan⁴,Wen Li²,Kong Hong-Xiao²,Zhi Li-Juan¹,Jacqz-Aigrain Evelyne⁵⁶,Zhao Wei⁴⁷^ORCID

Affiliation:

1. Department of Pharmacy, Children's Hospital of Hebei Province, Shijiazhuang, China

2. Department of Paediatric Haematology-Oncology, Children's Hospital of Hebei Province, Shijiazhuang, China

3. Department of Pharmacy, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China

4. Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China

5. Department of Paediatric Pharmacology and Pharmacogenetics, Hôpital Robert Debré, APHP, Paris, France

6. University Paris Diderot, Sorbonne Paris Cité, Paris, France

7. Paediatric Research Institute, Children's Hospital of Hebei Province, Shijiazhuang, China

Abstract

Imipenem is widely used for the treatment of children with serious infections. Currently, studies on the pharmacokinetics of imipenem in children with hematological malignancies are lacking.

Funder

National Science and Technology Major Projects

Scientific Research Foundation for the High-Level Returned Overseas Chinese Scholars

Hundred-Talent Program

Young Research Programme of the Health and Family Planning Commission of Hebei Province

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00006-19

Reference33 articles.